These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9747459)

  • 1. Superiority of the ear pinna over muscle tissue as site for DNA vaccination.
    Förg P; von Hoegen P; Dalemans W; Schirrmacher V
    Gene Ther; 1998 Jun; 5(6):789-97. PubMed ID: 9747459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine.
    Schirmacher V; Förg P; Dalemans W; Chlichlia K; Zeng Y; Fournier P; von Hoegen P
    Gene Ther; 2000 Jul; 7(13):1137-47. PubMed ID: 10918481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Attenuated Salmonella typhimurium as DNA delivery vehicle for DNA-mediated immunization].
    He P; Chen H; Liu JX; Chen SY; Hu BY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):238-42. PubMed ID: 15640857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle.
    Grønevik E; von Steyern FV; Kalhovde JM; Tjelle TE; Mathiesen I
    J Gene Med; 2005 Feb; 7(2):218-27. PubMed ID: 15515140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer.
    Song K; Chang Y; Prud'homme GJ
    Gene Ther; 2000 Mar; 7(6):481-92. PubMed ID: 10757021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors.
    Mitchell M; Jerebtsova M; Batshaw ML; Newman K; Ye X
    Gene Ther; 2000 Dec; 7(23):1986-92. PubMed ID: 11175309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
    Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
    Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
    Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
    Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells.
    Müller M; Gounari F; Prifti S; Hacker HJ; Schirrmacher V; Khazaie K
    Cancer Res; 1998 Dec; 58(23):5439-46. PubMed ID: 9850077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
    Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
    J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.
    Takeda J; Sato Y; Kiyosawa H; Mori T; Yokoya S; Irisawa A; Miyata M; Obara K; Fujita T; Suzuki T; Kasukawa R; Wanaka A
    Cell Immunol; 2000 Aug; 204(1):11-8. PubMed ID: 11006013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.
    Weeratna RD; Wu T; Efler SM; Zhang L; Davis HL
    Gene Ther; 2001 Dec; 8(24):1872-8. PubMed ID: 11821941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses limit adenovirally mediated gene expression in the adult mouse eye.
    Reichel MB; Ali RR; Thrasher AJ; Hunt DM; Bhattacharya SS; Baker D
    Gene Ther; 1998 Aug; 5(8):1038-46. PubMed ID: 10326026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic and therapeutic intervention in IgE responses by biolistic DNA vaccination primarily targeting dendritic cells.
    Sudowe S; Ludwig-Portugall I; Montermann E; Ross R; Reske-Kunz AB
    J Allergy Clin Immunol; 2006 Jan; 117(1):196-203. PubMed ID: 16387606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of a potent tumor vaccine-induced secondary anti-tumor T cell response.
    Mahnke YD; Schirrmacher V
    Int J Oncol; 2004 Jun; 24(6):1427-34. PubMed ID: 15138584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.